CA-3208235-C - COMPOSITIONS COMPRISING MAGNOLIA, PHELLODENDRON, THEANINE AND/OR WHEY PROTEIN

Abstract

Provided herein is an anxiolytic composition including a synergistic combination of L-theanine, at least one of magnolia and an extract of magnolia, and at least one of phellodendron and an extract of phellodendron. Also provided herein is a synergistic combination of L-theanine, at least one of magnolia and an extract of magnolia, and at least one of phellodendron and an extract of phellodendron, for use in reducing, ameliorating or treating symptoms of anxiety.

Inventors

• Todd Henderson
• David Griffin
• David Bledsoe

Assignees

• NUTRAMAX LABORATORIES, INC.

Dates

Publication Date

20260505

Application Date

20160831

Priority Date

20150831

Claims (20)

1. 18 WHAT IS CLAIMED IS: 1. An anxiolytic composition, comprising a synergistic combination of L-theanine, at least one of magnolia and an extract of magnolia, and at least one of phellodendron and an extract of phellodendron.
2. 2. The anxiolytic composition of claim 1 including the extract of magnolia.
3. 3. The anxiolytic composition of claim 2, wherein the extract of magnolia is an extract of Magnolia officinalis.
4. 4. The anxiolytic composition of claim 3, wherein the extract of Magnolia officinalis includes at least one of honokiol and magnolol.
5. 5. The anxiolytic composition of claim 1 including the extract of phellodendron.
6. 6. The anxiolytic composition of claim 5, wherein the extract of phellodendron is an extract of Phellodendron amurense.
7. 7. The anxiolytic composition of claim 6, wherein the extract of Phellodendron amurense includes berberine.
8. 8. The anxiolytic composition of claim 1 including the extract of magnolia and the extract of phellodendron, wherein the extract of magnolia is an extract of Magnolia officinalis, and the extract of phellodendron is an extract of Phellodendron amurense.
9. 9. The anxiolytic composition of claim 1, wherein the synergistic combination provides an anxiolytic change in a release pattern of one or more neurotransmitters.
10. 10. The anxiolytic composition of claim 9, wherein the neurotransmitters are brain neurotransmitters selected from the group consisting of glutamate and γ-aminobutyric acid (GABA).
11. 11. The anxiolytic composition of claim 1, further including s-adenosylmethionine 19 (SAMe).
12. 12. The anxiolytic composition of claim 11, wherein the s-adenosylmethionine (SAMe) comprises a SAMe phytate salt.
13. 13. A synergistic combination of L-theanine, at least one of magnolia and an extract of magnolia, and at least one of phellodendron and an extract of phellodendron, for use in reducing, ameliorating or treating symptoms of anxiety.
14. 14. The synergistic combination for use of claim 13, wherein the synergistic combination includes the extract of magnolia.
15. 15. The synergistic combination for use of claim 14, wherein the extract of magnolia is an extract of Magnolia officinalis.
16. 16. The synergistic combination for use of claim 13, wherein the synergistic combination includes the extract of phellodendron.
17. 17. The synergistic combination for use of claim 16, wherein the extract of phellodendron is an extract of Phellodendron amurense.
18. 18. The synergistic combination for use of claim 13, wherein the synergistic combination includes the extract of magnolia and the extract of phellodendron, wherein the extract of magnolia is an extract of Magnolia officinalis, and the extract of phellodendron is an extract of Phellodendron amurense.
19. 19. The synergistic combination for use of claim 13, wherein the synergistic combination provides an anxiolytic change in a release pattern of one or more neurotransmitters, and the neurotransmitters are brain neurotransmitters selected from the group consisting of glutamate and γ-aminobutyric acid (GABA).
20. 20. The synergistic combination for use of claim 13, wherein the synergistic combination is formulated of oral administration.

Description

COMPOSITIONS COMPRISING MAGNOLIA, PHELLODENDRON, THEANINE AND/OR WHEY PROTEIN CROSS REFERENCE [0001] This application is a divisional of Canadian Patent Application No. 2,995,395 filed on August 31, 2016, and claims priority to U.S. Provisional Patent Application Serial No. 62/212,080 filed on August 31, 2015. TECHNICAL FIELD [0002] The present application relates generally to anxiolytic compositions containing magnolia, phellodendron, theanine, a whey protein, and/or s-adenosylmethionine. BACKGROUND [0003] Anxiety, fear, and stress play major roles or contribute in some way to many human and non-human animal behavioral disorders. For example, with regard to canines and felines, storm phobias, noise phobias, social avoidance, fear-related aggression, compulsive disorders, and submissive urination have obvious anxiety components, but even problems such as urine marking, territorial aggression, and resource guarding can be fueled by fear or anxiety. Fear and anxiety disorders affect an estimated 23 million dogs in the US at a cost of more than $1 billion in treatment and property damage. Of dogs relinquished to shelters, perhaps 40% or more are abandoned due to behavioral issues, while 14% of cats are surrendered due to behavioral problems. In pet cats, behavior problems are still the most common cause of euthanasia. In a recent survey of pet owners, 41 % of dog owners reported that they have owned a dog with anxiety issues at some time, with 29% of currently-owned dogs being affected. The most prevalent types of anxiety reported by these owners included noise phobia (17% ), separation anxiety (13%), and generalized anxiety (5%). [0004] Anxiety in horses is similarly a common problem in the equine industry, contributing to behavioral problems, training issues and poor performance. In some cases, increased levels of anxiety are associated with health related issues such as gastric ulcers, which have been shown in some studies to impact a large percentage of horses. Manifestations of anxiety in horses is commonly seen not only in the form of gastric ulcers, but also is expressed behaviorally in the form of bolting, jumping, panicking, trailering difficulties, pacing, stall weaving, pawing, and biting. The most common risk factor for anxiety disorders in dogs appears to be acquisition from animal shelters or multiple foster homes, with up to 68.3% of 1 Date Re9ue/Date Received 2023-07-31 dogs adopted from shelters exhibiting some type of anxiety disorder. One retrospective study on behavior diagnoses indicates possible breed predilections in Dalmatians, English springer spaniels, German shepherd dogs, and mixed breed dogs, while another study suggests cocker spaniels, schnauzers, and dachshunds may be at risk for developing separation anxiety. The incidence of anxiety disorders does appear to increase with age, most likely due to a loss of cognitive function, from an incidence of 22.5% in dogs less than 3 years of age to an incidence of 36.5% in dogs 8 years of age and over. [0005] Fear is an emotional response due to the presence of a specific stimulus (object, noise, individual, etc.) that the pet perceives as a threat or a danger. In contrast, an anxiety is a reaction of apprehension or uneasiness to an anticipated danger or threat. Anxiety, therefore, may be displayed in the absence of an identifiable stimulus, whereas with fear, a stimulus can usually be identified. While anxiety and the accompanying physiological stress are unlikely to be pathologic in the short-term, when stress and anxiety become a chronic state, the health, welfare, and lifespan of the pet may become compromised. Therefore, to provide optimum health and welfare for all pets, veterinary healthcare practitioners consider anxiety as an additional possible disease state in companion animals. At the extreme end of the spectrum, a phobia is a profound, excessive, abnormal fear response that occurs without the presence of a true threat or is out of proportion to the needs for dealing with an actual threat. While fears may be normal adaptive responses, phobias are abnormal, maladaptive, and typically interfere with normal function. Anxiety, which inhabits the middle of the spectrum, is often overlooked or misunderstood, but may have a significant impact on a pet's daily well-being. [0006] Clinical signs of fear and anxiety in dogs include hypervigilance, elimination, destruction, excessive vocalization, hyper-salivation, panting, hiding, trembling, and escape behaviors. In cats, chronic anxiety and fear can also lead to secondary behavioral problems such as over-grooming, spraying, and inter-cat aggression, and can predispose the cat to health problems owing to a compromised immune system. Since most of the clinical signs of fear and anxiety are destructive and distressing to both pet and owner, one can easily understand why pet owners would be likely to seek out advice for such disorders. Not coincidentally, the most common risk factors for re